1-7 of 7
Elke Jäger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial

Matthias Kloor, Miriam Reuschenbach, Claudia Pauligk, Julia Karbach, Mohammad-Reza Rafiyan, Salah-Eddin Al-Batran, Mirjam Tariverdian, Elke Jäger, Magnus von Knebel Doeberitz
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4503–4510.
https://doi.org/10.1158/1078-0432.CCR-19-3517
Published: 01 September 2020
View article titled, A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial
Open the PDF for A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

Bernardo Sgarbi Reis, Achim A. Jungbluth, Denise Frosina, Megan Holz, Erika Ritter, Eiichi Nakayama, Toshiaki Ishida, Yuichi Obata, Brett Carver, Howard Scher, Peter T. Scardino, Susan Slovin, Sumit K. Subudhi, Victor E. Reuter, Caroline Savage, James P. Allison, Jonathan Melamed, Elke Jäger, Gerd Ritter, Lloyd J. Old, Sacha Gnjatic
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (22): 6112–6125.
https://doi.org/10.1158/1078-0432.CCR-12-3580
Published: 14 November 2013
View article titled, Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein
Open the PDF for Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein in another window
Includes: Supplementary data
Journal Articles

Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity

Julia Karbach, Antje Neumann, Kathrin Brand, Claudia Wahle, Ekkehard Siegel, Markus Maeurer, Erika Ritter, Takamasa Tsuji, Sacha Gnjatic, Lloyd J. Old, Gerd Ritter, Elke Jäger
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5449–5459.
https://doi.org/10.1158/1078-0432.CCR-12-1116
Published: 30 September 2012
View article titled, Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
Open the PDF for Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity in another window
Includes: Supplementary data
Journal Articles

Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients

Julia Karbach, Antje Neumann, Akin Atmaca, Claudia Wahle, Kathrin Brand, Lotta von Boehmer, Alexander Knuth, Armin Bender, Gerd Ritter, Lloyd J. Old, Elke Jäger
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 861–870.
https://doi.org/10.1158/1078-0432.CCR-10-1811
Published: 15 February 2011
View article titled, Efficient <em>In vivo</em> Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients
Open the PDF for Efficient <em>In vivo</em> Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients in another window
Includes: Supplementary data
Journal Articles

An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors

Ralf-Dieter Hofheinz, Salah-Eddin Al-Batran, Andreas Hochhaus, Elke Jäger, Volker L. Reichardt, Holger Fritsch, Dirk Trommeshauser, Gerd Munzert
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (18): 4666–4674.
https://doi.org/10.1158/1078-0432.CCR-10-0318
Published: 14 September 2010
View article titled, An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors
Open the PDF for An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

The Cytoskeleton Regulatory Protein hMena (ENAH) Is Overexpressed in Human Benign Breast Lesions with High Risk of Transformation and Human Epidermal Growth Factor Receptor-2–Positive/Hormonal Receptor–Negative Tumors

Francesca Di Modugno, Marcella Mottolese, Anna Di Benedetto, Andrea Conidi, Flavia Novelli, Letizia Perracchio, Irene Venturo, Claudio Botti, Elke Jager, Angela Santoni, Pier Giorgio Natali, Paola Nisticò
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (5): 1470–1478.
https://doi.org/10.1158/1078-0432.CCR-05-2027
Published: 06 March 2006
View article titled, The Cytoskeleton Regulatory Protein hMena (ENAH) Is Overexpressed in Human Benign Breast Lesions with High Risk of Transformation and Human Epidermal Growth Factor Receptor-2–Positive/Hormonal Receptor–Negative Tumors
Open the PDF for The Cytoskeleton Regulatory Protein hMena (ENAH) Is Overexpressed in Human Benign Breast Lesions with High Risk of Transformation and Human Epidermal Growth Factor Receptor-2–Positive/Hormonal Receptor–Negative Tumors in another window
Includes: Supplementary data
Journal Articles

5-aza-2′-Deoxycytidine-induced Expression of Functional Cancer Testis Antigens in Human Renal Cell Carcinoma: Immunotherapeutic Implications

Sandra Coral, Luca Sigalotti, Maresa Altomonte, Arne Engelsberg, Francesca Colizzi, Ilaria Cattarossi, Eugene Maraskovsky, Elke Jager, Barbara Seliger, Michele Maio
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (8): 2690–2695.
Published: 01 August 2002
View article titled, 5-aza-2′-Deoxycytidine-induced Expression of Functional Cancer Testis Antigens in Human Renal Cell Carcinoma: <subtitle>Immunotherapeutic Implications</subtitle>
Open the PDF for 5-aza-2′-Deoxycytidine-induced Expression of Functional Cancer Testis Antigens in Human Renal Cell Carcinoma: <subtitle>Immunotherapeutic Implications</subtitle> in another window